Acousia Therapeutics Reports Breakthrough Results in Hearing Loss Treatment with ACOU085

Promising First-in-Patient Results for ACOU085

In a significant advancement for treating chemotherapy-induced hearing loss, Acousia Therapeutics GmbH announced successful outcomes from their Phase 2a PROHEAR Study on ACOU085, also known as Bimokalner. This clinical-stage biotechnology company focuses on developing innovative solutions for acute and chronic inner ear hearing loss.

Study Highlights

The PROHEAR Study, which utilized a randomized, placebo-controlled design, tested the efficacy of a 6 mg transtympanic dose of ACOU085 on patients at risk of hearing loss due to cisplatin treatment for testicular cancer. The findings showed that more than 90% of participants, who were otherwise hearing-healthy, experienced ototoxicity in at least one ear after receiving three cycles of cisplatin (300 mg/m²), primarily in the extended high-frequency range (10-16 kHz).

The statistics are particularly concerning as patients confirmed with ototoxicity exhibited increases in pure-tone audiometry (PTA) threshold at those frequencies. However, the administration of ACOU085 significantly mitigated this hearing deterioration when compared to the placebo group, showcasing its potential in preserving hearing integrity during chemotherapy.

Clinical Implications

This milestone signals a crucial opportunity for patients undergoing cisplatin-based chemotherapy, which often results in irreversible damage to the cochlea's outer hair cells, leading to permanent hearing loss. The innovative treatment approach demonstrates the activation of the Kv7.4 potassium channel in outer hair cells as a restorative target.

Professor Hubert Löwenheim from Tübingen University Medical Center, who oversaw the study, emphasized that this is a pivotal moment in developing a novel therapeutic pathway for various types of hearing impairment. He reiterated the inadequacy of existing device-based solutions and highlighted the essential need for such pharmacological interventions.

Future Directions

Following these encouraging results, Acousia Therapeutics plans to further analyze ongoing study data, as they prepare for submission to a peer-reviewed medical journal. Tim Boelke, the CEO and CMO of Acousia Therapeutics, expressed enthusiasm regarding the potential of ACOU085 to change outcomes for cancer patients, as it offers a proactive solution to prevent the auditory damage commonly associated with cisplatin treatment.

The team will actively participate in the upcoming BIO International Convention from June 22-25, 2026, in San Diego, seeking collaborations that can catalyze the next phases of clinical development for ACOU085.

Conclusion

With the promising results from the PROHEAR Study, ACOU085 stands on the verge of addressing a substantial unmet medical requirement in the oncology sector. It holds the promise to improve the quality of life for numerous patients facing the devastating side effects of cisplatin chemotherapy, marking a significant leap in the field of otoprotective therapies.

For further inquiries about the ongoing research and potential partnership discussions, contact Acousia Therapeutics at [email protected] or visit their official website at www.acousia.com.